August 3rd 2021
Eytan Stein, MD, discusses the management of chemotherapy-ineligible AML, as well as the effect of venetoclax in combination with HMA as a new therapy.
May 19th 2021
Best practices for the use of gene profiling assays to guide treatment decisions for patients with early-stage HR-positive breast cancer.
May 3rd 2021
Sagar Lonial, MD, FACP, explains the various ways to target and treat relapsed/refractory multiple myeloma, specifically focusing on BCMA and belantamab mafoditin as therapeutic agents.
April 1st 2021
Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.
February 9th 2021
Anthony Lucci, MD, provides insight on the management of early-stage breast cancer and evolving therapeutic approaches for patients due to the COVID-19 pandemic.
January 20th 2021
Thomas Herzog, MD, provides insight on key clinical trials and the use of PARP inhibition in frontline maintenance therapy for ovarian cancer.
October 27th 2020
BCMA targeting agents such as the antibody-drug conjugate belantamab mafodotin show promise for heavily pretreated patients with relapsed/refractory multiple myeloma
October 9th 2020
The rationale for using BCMA-targeted novel approaches such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies as treatment for patients with heavily pretreated relapsed/refractory multiple myeloma.
June 16th 2020
ONCOLOGY® recently sat down with Jane L. Meisel, MD, of Emory University School of Medicine in Atlanta, Georgia, to discuss how these data from the TAILORx trial validate and inform the current and future care of patients with breast cancer.